Bristol Myers Squibb (CELG-RI) Depreciation and Depletion (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Depreciation and Depletion data on file, last reported at $139.0 million in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $139.0 million, down 15.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $595.0 million (down 9.98% YoY), and the FY2025 annual result was $621.0 million, down 4.61% from the prior year.
• Depreciation and Depletion grew to $139.0 million in Q1 2026 per CELG-RI's latest filing, from $132.0 million in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $169.0 million in Q4 2024 and troughed at $132.0 million in Q4 2025.
• A 5-year average of $153.5 million and a median of $153.0 million in 2022 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2022 and 2025: Depreciation and Depletion advanced 11.68% in 2022, then fell 21.89% in 2025.
• A 5-year view of Depreciation and Depletion shows it stood at $153.0 million in 2022, then increased by 6.54% to $163.0 million in 2023, then gained by 3.68% to $169.0 million in 2024, then slipped by 21.89% to $132.0 million in 2025, then gained by 5.3% to $139.0 million in 2026.
• Business Quant data shows CELG-RI's Depreciation and Depletion at $139.0 million in Q1 2026, $132.0 million in Q4 2025, and $159.0 million in Q3 2025.